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Introduction {#sec001}
============

The slow afterhyperpolarization (sAHP) has been first characterized nearly 40 years ago as a Ca^2+^-dependent K^+^ potential following action potentials or epileptiform bursts in hippocampal CA1 pyramidal neurons \[[@pone.0230465.ref001], [@pone.0230465.ref002]\]. Functionally, the sAHP is responsible for the late phase of spike frequency adaptation and leads to a strong reduction or a complete cessation of action potential firing, thereby controlling the repetitive firing of neurons and limiting the numbers of action potentials generated in response to stimuli \[[@pone.0230465.ref003], [@pone.0230465.ref004]\]. Voltage-clamp studies have revealed that the current, sI~AHP~, underlying the sAHP reaches its maximum with a time constant of several hundred milliseconds and decays with a time constant of \>1s, and the kinetics of the current are temperature dependent \[[@pone.0230465.ref005], [@pone.0230465.ref006]\].

Activation of the sI~AHP~ requires Ca^2+^ influx and an increase in intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~), as the current is suppressed by removing extracellular Ca^2+^ \[[@pone.0230465.ref001], [@pone.0230465.ref006]\], blocking Ca^2+^ channels \[[@pone.0230465.ref001], [@pone.0230465.ref002], [@pone.0230465.ref005], [@pone.0230465.ref006]\] or perfusing neurons with Ca^2+^ chelators, EGTA or BAPTA \[[@pone.0230465.ref006]\]. The Ca^2+^ sources that contribute to the activation of this current (sI~AHP~) and generate the afterhyperpolarising potential (sAHP) include voltage-gated calcium channels (VGCCs), whose subtypes vary in different neurons. In the hippocampus, the use of selective inhibitors for different VGCC subtypes has revealed that activation of L-type calcium channels substantially contributes to the generation of sI~AHP~/sAHP in both CA1 and CA3 pyramidal neurons \[[@pone.0230465.ref007]--[@pone.0230465.ref010]\]. Mice in which the gene encoding Ca~V~1.3 was deleted have further demonstrated that Ca~V~1.3 channels play a predominant role for the generation of sAHP in CA1 pyramidal neurons \[[@pone.0230465.ref011]\].

Two peculiar features of the sI~AHP~ and sAHP cannot be explained by a linear dependence on Ca^2+^ influx through VGCCs. The first is that the time to peak of their amplitude reaches its maximum value \~500 ms after the end of Ca^2+^ entry during action potentials \[[@pone.0230465.ref012]\]. The second is the phenomenon of activity-dependent potentiation, often referred to as "run-up", whereby repeated stimulation of cortical pyramidal neurons by depolarizing current pulses causes a marked and sustained increase in the sI~AHP~/sAHP amplitude with a concomitant reduction in neuronal excitability \[[@pone.0230465.ref013]--[@pone.0230465.ref017]\]. For each of these features Ca^2+^-induced Ca^2+^ release (CICR), where Ca^2+^ entering through VGCCs causes a secondary transient elevation of intracellular Ca^2+^ levels due to the activation of ryanodine receptors and the release of Ca^2+^ from endoplasmic reticulum stores, has been proposed as a potential underlying mechanism \[[@pone.0230465.ref014], [@pone.0230465.ref018]--[@pone.0230465.ref021]\].

In hippocampal neurons, ryanodine receptors (RyR) are expressed on the endoplasmic reticulum throughout the cell, including axons, dendrites and dendritic spines \[[@pone.0230465.ref022]\]. In situ hybridisation studies have revealed that type 3 ryanodine receptors (RyR3) are highly expressed, being indeed the predominant RyR subtype, in CA1 neurons of the rodent hippocampal formation, with a relatively lower level of expression in CA3 neurons \[[@pone.0230465.ref023]--[@pone.0230465.ref025]\]. Both CA1 and CA3 pyramidal neurons express also type 1 (RyR1) and type 2 (RyR2) receptors \[[@pone.0230465.ref023]--[@pone.0230465.ref025]\].

Ryanodine-sensitive calcium stores in CA1 pyramidal neurons contain a releasable pool of calcium that is maintained by calcium entry through voltage-gated calcium channels \[[@pone.0230465.ref026], [@pone.0230465.ref027]\]. Ca^2+^ influx evoked by either a single or multiple action potentials triggers RyR-mediated CICR from these stores, thereby increasing the overall magnitude of action potential-induced Ca^2+^ signals \[[@pone.0230465.ref028]\]. This action potential-induced Ca^2+^ elevation is essential to elicit the sAHP/sI~AHP~, but the actual contribution of RyR-mediated CICR to the generation of this afterpotential and K^+^ current in CA1 neurons is controversial in the existing literature. Some studies show that sAHP/sI~AHP~ is at least partly dependent on RyR-mediated CICR \[[@pone.0230465.ref014], [@pone.0230465.ref021], [@pone.0230465.ref029]--[@pone.0230465.ref031]\], and particularly on RyR3 \[[@pone.0230465.ref032]\], while other studies confute any role of RyR-mediated CICR in the generation of sAHP/sI~AHP~ \[[@pone.0230465.ref017]\].

Here we have addressed the impact of RyR-mediated CICR on the amplitude of the sI~AHP~ at steady state and on its activity-dependent potentiation in rat and mouse hippocampal pyramidal neurons, and we have focused in particular on the role played by RyR3 in the regulation of sI~AHP~ in CA1 neurons by studying mice specifically lacking type 3 ryanodine receptors.

Materials and methods {#sec002}
=====================

Ryanodine receptor type 3 deficient mice {#sec003}
----------------------------------------

Mice deficient in the ryanodine receptor type 3 gene (RyR3 −/−) were generated by homologous recombination, replacing exon 2 with a neomycin cassette, as described previously \[[@pone.0230465.ref033]\]. No Ryr3 protein was detected by Western blot analysis of brain tissue from RyrR −/− mice \[[@pone.0230465.ref033]\]. Mice were kept on a C57BL/6Jx129S4 background, and genotypes were confirmed by PCR on genomic DNA. All animal procedures were in accordance with the UK Animals (Scientific Procedures) Act 1986 and reviewed and approved by the UCL Animal Welfare and Ethical Review Body. Wild-type littermates (RyR3 +/+) from heterozygous crossings were used as internal controls. Experimenters remained blind to the genotype of RyR3 mice during experimentation and data analysis.

Slice preparation {#sec004}
-----------------

Acute slices were obtained from 21--28 days old Sprague Dawley rats or 3--5 months old RyR3 (RyR3 −/−; RyR3 *+/+*) mice. Animals were anaesthetized with isoflurane, decapitated and horizontal (from mouse) or transversal (from rat) hippocampal slices (350 μm thick) were obtained using a vibratome (LeicaVT1000s, Leica, Germany) and were subsequently incubated in a humidified interface chamber at room temperature for ≥1 hr.

Electrophysiology {#sec005}
-----------------

Tight-seal whole-cell patch clamp recordings were obtained from CA1 pyramidal neurons using the "blind patching technique" \[[@pone.0230465.ref034]\]. Experiments were conducted either with an EPC9 or an EPC10 amplifier (HEKA, Germany) controlled by Pulse or PatchMaster software for data acquisition (HEKA, Germany). Slices were perfused in a submerged recording chamber with a constant flow of 2--2.5 ml/min with carbogen-bubbled ACSF containing (in mM: 125 NaCl, 1.25 KCl, 2.5 CaCl~2~, 1.5 MgCl~2~, 1.25 KH~2~PO~4~, 25 NaHCO~3~, and 16 D-glucose) and the sI~AHP~ was recorded at room temperature (22±1°C) with patch pipettes made of borosilicate glass (Hilgenberg, Germany), with a resistance of 4.5--7.5 MOhm when filled with intracellular solution. For recordings from rat CA1 pyramidal neurons, the pipette solution used contained (in mM): 135 K-gluconate, 10 KCl, 10 HEPES, 2 Na~2~ATP, 0.4 Na~3~GTP 0.4 and 1 MgCl~2~. For recordings from mouse CA1 pyramidal neurons, the pipette solution contained (in mM): 135 K-MeSO~4~, 10 KCl, 10 HEPES, 2 Na~2~ATP, 0.4 Na~3~GTP and 1 MgCl~2~. The pH was adjusted to 7.2--7.3 with KOH and the osmolarity of the intracellular solution was between 280--290 mOsm/kg. Only cells with a resting membrane potential ≤-55 mV and a series resistance ≤30 MOhm, not changing by more than 25% in the course of the experiment, were included in this study. Voltage values reported were not corrected for the liquid junction potential that was -11 mV (intracellular K-gluconate solution) and -5 mV (intracellular K-MeSO~4~ solution).

Action potentials were elicited by 40--100 pA, 1 s-long current injections repeated and increased by further 40--100 pA every 20 s. Data were filtered at 3 kHz and sampled at 12.5 kHz. Series resistance, input resistance and membrane time constant (τ) of CA1 pyramidal neurons were measured in response to 100 ms-long voltage steps of -5mV from a holding potential of -50 mV; data were filtered at 5 kHz and sampled at 20 kHz.

The sI~AHP~ was measured as an outward current and elicited by stepping to +10 mV for 100 ms from a holding potential of -50 mV every 30 seconds to slightly increase the driving force for K^+^, activate voltage-gated Ca^2+^ channels and obtain Ca^2+^ influx necessary to activate the sI~AHP~. Traces data were sampled at 1 kHz and filtered at 250 Hz. In all voltage-clamp recordings we added to the superfusing ACSF tetrodotoxin (TTX, 0.5 μM) to block voltage-gated sodium channels, and tetraethylammonium (TEA, 1 mM) to block a subset of voltage-gated potassium channels and increase calcium influx and thereby the calcium dependent sI~AHP~. In recordings from mouse CA1 pyramidal neurons, also d-tubocurarine hydrochloride (dTC, 100 μM) was added to the ACSF to inhibit SK channels. 10 μM Ryanodine was applied either for \~15 minutes after sI~AHP~ had reached a steady state amplitude (i.e. upon completion of the potentiation phase) or for the whole duration of the whole-cell recording to study its impact on the sI~AHP~ potentiation. In some experiments (Rp)-Adenosine-3\`,5\`-monophosphorothioate (Rp-cAMPS, 500 μM) was added to the intracellular solution to inhibit protein kinase A (PKA).

Data analysis and statistics {#sec006}
----------------------------

All experiments were analysed using the software Pulsefit (HEKA, Germany) and IGOR Pro (Wavemetrics, USA) with the support of Neuromatic \[[@pone.0230465.ref035]\]. The amplitude of the sI~AHP~ was measured 700--1000 ms after the end of the command pulse, when possible contamination by other, faster outward currents are negligible \[[@pone.0230465.ref036]\]. The charge transfer was determined as the area under the curve starting from the sI~AHP~ peak until full decay had occurred. The deactivation time constant (τ~decay~) was obtained by fitting a mono-exponential function to the data points.

The amplitudes of 2--3 traces around a given time-point or before and after drug application were averaged to quantify potentiation or drug effects, as shown in summary bar diagrams and box and whisker plots.

The activity-dependent potentiation (run-up) was calculated by normalising the sI~AHP~ amplitude to the amplitude recorded at 0 min. The corresponding time constant of sI~AHP~ potentiation (τ~potentiation~) was calculated by fitting a mono-exponential function to the first 15 minutes of the run-up phase. To quantify the potentitation, sI~AHP~ amplitudes were measured at the start (0 min) and the end (15 min) of the potentiation, and used to calculate the ratio (sI~AHP~ (15 min)/sI~AHP~ (0 min)).

All graphs were created using Prism 6 (GraphPad, USA), which was also used for the statistical analysis, together with InStat (GraphPad, USA). In box-and-whiskers plots, the boxes extend from the 25th to 75th percentiles, the lines in the middle of the boxes represent the median, the circles correspond to the mean and the whiskers stretch to the smallest and largest values in each data set. Mean and standard error of the mean (mean ± SEM) were used to describe the results of statistical analysis, as shown in bar diagrams and for the data points in the graphs showing the relative (%) time-courses of potentiation. When not otherwise specified, for data with normal distributions, paired or unpaired t-tests or ANOVA were used for comparisons; when data were not normally distributed, appropriate non-parametric tests or corrections were employed to calculate statistical significance, as specified in the text. (\*) indicates statistical significance (P\<0.05).

Drugs and solutions {#sec007}
-------------------

Ryanodine was obtained from Calbiochem (Millipore, Heartfordshire, UK) and Alomone Labs (Israel); cyclopiazonic acid (CPA) from Alomone Labs (Israel); caffeine from Calbiochem (Millipore, Heartfordshire, UK); KMeSO~4~ from Fisher Scientific (Loughborough, UK); tetrodotoxin (TTX) citrate-free from Latoxan (Rosans, France); d-tubocurarine hydrochloride (dTC), Na~2~ATP, Na~3~GTP and tetraethylammonium (TEA) from Sigma-Aldrich (Dorset, UK); (Rp)-Adenosine-3\`,5\`-monophosphorothioate (Rp-cAMPS) (BioLog Life Science Institute, Germany). All other salts and chemicals were obtained from Sigma-Aldrich or VWR International Ltd. Drugs were dissolved in water or DMSO, stored at +4°C or -20°C, and bath applied in the perfusing ACSF.

Results {#sec008}
=======

RyR-mediated CICR affects sI~AHP~ and its potentiation in rat CA1 pyramidal neurons {#sec009}
-----------------------------------------------------------------------------------

The impact of Ca^2+^-induced Ca^2+^ release (CICR) on the sI~AHP~ in rat CA1 pyramidal neurons was studied with a set of pharmacological tools targeting ryanodine receptor (RyR)-mediated CICR. The effects of these compounds on both the steady-state amplitude and the activity-dependent potentiation of the sI~AHP~ were assessed.

Whole cell voltage-clamp recordings were obtained from 72 CA1 pyramidal neurons in rat hippocampal slices. sI~AHP~ was elicited as a tail current following an inward Ca^2+^ current activated by a 100 ms long depolarizing voltage step from -50 mV to +10 mV which was repeated every 30 s. The mean resting membrane potential in all measured cell was -59.5 ± 0.4 mV (n = 72) and the mean amplitude of sI~AHP~ at steady-state was 59.3 ± 3.7 pA (n = 72).

Caffeine enhances sI~AHP~ in rat CA1 pyramidal neurons {#sec010}
------------------------------------------------------

The methylxanthine caffeine binds to the ryanodine receptors and, when used at a low concentration (0.5 mM) \[[@pone.0230465.ref037]\], enhances the increase in intracellular Ca^2+^ due to Ca^2+^ release from the ryanodine-sensitive stores \[[@pone.0230465.ref027], [@pone.0230465.ref038], [@pone.0230465.ref039]\]. Therefore, we tested whether the application of caffeine at this concentration affected the sI~AHP~.

A biphasic effect of caffeine (0.5 mM) on the sI~AHP~ amplitude ([Fig 1A--1E](#pone.0230465.g001){ref-type="fig"}) was observed in 16 cells. In these cells, the sI~AHP~ amplitude first increased by \~25% (P \< 0.0001), followed by a decrease by \~25% when compared to the amplitude of the current preceding caffeine application. In a further six cells the same increase in the sI~AHP~ amplitude was observed, but the recording condition became unstable before the time point to estimate the amplitude reduction was reached.

![Effect of caffeine on sI~AHP~ in rat CA1 neurons.\
**(A)** Representative sI~AHP~ trace at steady state. **(B)** sI~AHP~ trace maximally enhanced after 2.5 min into the application of caffeine (0.5 mM). **(C)** sI~AHP~ reduction after continuous application of caffeine. **(D)** Time course of action of caffeine (0.5 mM) on the sI~AHP~ amplitude. Data point in black and indicated by arrows correspond to traces **(A-C)**. **(E)** Summary bar diagram, showing that the sI~AHP~ amplitude first increased by 25.3 ± 2.9% (**max**: n = 22; P \< 0.0001), followed by a decrease by 24.5 ± 3.6% at steady state (**ss**: n = 16; P \< 0.0001) when compared to the current amplitude preceding caffeine application. **(F)** Representative sI~AHP~ trace recorded at steady state but with the PKA inhibitor Rp-cAMPS (500 μM) applied intracellularly. **(G)** sI~AHP~ current increase in the presence of Rp-cAMPS and after \~17.5 min application of caffeine (0.5 mM), a time point comparable to (**C**). **(H)** Overlay of the sI~AHP~ traces in **F** and **G**. (**I)** Time course of action of caffeine (0.5 mM) in the presence of Rp-cAMPS; (**ss-Rp**) indicates the trace shown in **G**. **(J)** Bar diagram comparing the relative (%) changes in sI~AHP~ amplitude in response to caffeine application at steady state in the absence (**ss**; of panel **E**) and presence of the PKA inhibitor Rp-cAMPS (**ss-Rp**). sI~AHP~ amplitude increased by 29.8 ± 7.9% (**ss-Rp**: n = 4; P = 0.03) in the presence of Rp-cAMPS after caffeine application when compared to the sI~AHP~ current amplitude preceding caffeine application. The difference between the effect of caffeine with or without Rp-cAMPS is highly significant (P \< 10^−6^).](pone.0230465.g001){#pone.0230465.g001}

Beside enhancing CICR from intracellular Ca^2+^ stores, caffeine is also an effective inhibitor of phosphodiesterases \[[@pone.0230465.ref040], [@pone.0230465.ref041]\]. The inhibition of phosphodiesterases leads to an increase of intracellular cAMP known to inhibit the sI~AHP~ through activation of protein kinase A (PKA) \[[@pone.0230465.ref042], [@pone.0230465.ref043]\]. Therefore, if the observed decrease of the sI~AHP~ amplitude during prolonged caffeine application was due to the elevation of intracellular cAMP and consequent activation of PKA, then this effect should be prevented by inhibition of PKA. This hypothesis was tested by applying the specific PKA-inhibitor Rp-cAMPS (500 μM), which competitively inhibits cAMP-binding sites on the regulatory subunits of PKA \[[@pone.0230465.ref044]\], through the patch pipette and allowing its diffusion into the cell before the application of caffeine. In the presence of Rp-cAMPS, caffeine increased sI~AHP~ by a comparable percentage (29.8 ± 7.9%) as in the absence of Rp-cAMPS ([Fig 1F--1J](#pone.0230465.g001){ref-type="fig"}). However, this increase of sI~AHP~ amplitude was not followed by a decrease, supporting the hypothesis that indeed the decrease in sI~AHP~ was due to activation of PKA.

These results show that enhancement of intracellular Ca^2+^ levels caused by stimulation of ryanodine-sensitive stores by caffeine leads to an increase in sI~AHP~ amplitude. While this observation establishes a link between Ca^2+^ released from intracellular stores and sI~AHP~, it does not address the question as to whether CICR contributes to the activation of sI~AHP~ when the current is elicited in response to depolarizing stimuli that increases intracellular Ca^2+^ by activating voltage-gated Ca^2+^ channels.

Ryanodine reduces the sI~AHP~ amplitude at steady-state in rat CA1 pyramidal neurons {#sec011}
------------------------------------------------------------------------------------

To address the question of the concurrent involvement of RyR-mediated CICR in the generation of the sI~AHP~ elicited by activation of voltage-gated Ca^2+^ channels in response to depolarizing stimuli ryanodine was used. At a concentration of 10 μM ryanodine inhibits CICR and caffeine-induced Ca^2+^ signals \[[@pone.0230465.ref026], [@pone.0230465.ref027], [@pone.0230465.ref038]\] in CA1 pyramidal neurons.

Ryanodine (10 μM) was bath-applied once the sI~AHP~ had reached a stable amplitude, in order to assess its effect on the current at steady-state ([Fig 2A--2D](#pone.0230465.g002){ref-type="fig"}). In response to ryanodine, the amplitude of the sI~AHP~ decreased by \~23%, from 70.0 ± 2.8 pA to 53.5 ± 2.5 pA (n = 5; P = 0.004; [Fig 2B--2E](#pone.0230465.g002){ref-type="fig"}).

![Effect of ryanodine on the sI~AHP~ measured at steady state in rat CA1 pyramidal neurons.\
**(A)** Representative sI~AHP~ trace measured at steady state. **(B)** Reduction of the sI~AHP~ upon application of ryanodine (10 μM). (**C)** Superimposed traces before and after application of ryanodine. (**D)** Time course of action of ryanodine (10 μM) on the sI~AHP~ amplitude in the same cell as for the traces shown in panels **A-C**. **(E)** Summary bar diagram showing that ryanodine decreases the amplitude of the sI~AHP~ by 23.3 ± 3.7% (n = 5; P = 0.03). Data are normalised to the control, set as 100%.](pone.0230465.g002){#pone.0230465.g002}

This result suggests that in rat CA1 pyramidal neurons CICR from ryanodine-sensitive stores makes a small, but significant contribution to the generation of the sI~AHP~ primarily evoked in response to Ca^2+^ influx through voltage-gated Ca^2+^ channels activated by depolarizing stimuli.

Inhibition of CICR by ryanodine hinders the activity-dependent potentiation of sI~AHP~ in rat CA1 pyramidal neurons {#sec012}
-------------------------------------------------------------------------------------------------------------------

Repeated activation of CA1 pyramidal neurons by depolarizing pulses induces a reduction in excitability, most likely as a consequence of an increased sI~AHP~ \[[@pone.0230465.ref013], [@pone.0230465.ref015]\]. The activity-dependent potentiation or "run-up" \[[@pone.0230465.ref014], [@pone.0230465.ref017]\], a phase resulting in a substantial and sustained increase of sI~AHP~, has been attributed to an increase in intracellular Ca^2+^ \[[@pone.0230465.ref014], [@pone.0230465.ref016]\]. Therefore we addressed the question as to whether ryanodine-dependent CICR contributes to the sI~AHP~ potentiation in whole-cell patch clamp recordings.

A run-up phase of the sI~AHP~, lasting in average 15 min, was consistently observed in our recordings (e. g. Figs [1D, 1I](#pone.0230465.g001){ref-type="fig"} and [2D](#pone.0230465.g002){ref-type="fig"}). To analyse the run-up phase in more detail, TTX (0.5 μM) and TEA (1 mM) were added to the bath solution at least 3 minutes before recording the first sI~AHP~ trace, in order to exclude potential contributions induced by the sodium and potassium channel blockers to the sI~AHP~ amplitude increase. In control experiments (0.2% DMSO), the sI~AHP~ amplitude increased from 23.1 ± 5.1 pA to 79.0 ± 7.7 pA ([Fig 3A--3C, 3J and 3K](#pone.0230465.g003){ref-type="fig"}), a nearly 4 fold increase after 15 minutes (n = 5; Fig L, paired t-test: P = 0.0017), with 75% of the potentiation occurring already within the first 3 minutes ([Fig 3J and 3L](#pone.0230465.g003){ref-type="fig"}).

![CICR contributes to the activity-dependent potentiation of sI~AHP~ in rat CA1 pyramidal neurons.\
(**A-I)** Representative current traces at 0 min, 3 min and 15 min show the potentiation of the sI~AHP~. (**A-C)** Control traces recorded in the presence of 0.2% DMSO. (**D-F)** Reduced potentiation of the sI~AHP~ in the presence of 10 μM ryanodine. (**G-I)** Reduced potentiation of the sI~AHP~ in the presence of 50 μM CPA. (**J)** Superimposed time-courses of three representative cells comparing the different degrees of the potentiation of sI~AHP~ amplitude under control conditions, 10 μM ryanodine and 50 μM CPA. (**K)** Bar chart summarizing the sI~AHP~ amplitude at the beginning of the recording (0 min) and the end of the recording (15 min), (control, 0 min: 23.1 ± 5.1 pA; 15 min: 79.0 ± 7.7 pA; n = 5; paired t-test: P = 0.0017; 10 μM ryanodine, 0 min: 27.4 ± 2.6 pA; 15 min: 58.2 ± 9.3 pA; n = 5; paired t-test: P = 0.02; 50 μM CPA; 0 min: 27.5 ± 6.6 pA; 15 min: 39.2 ± 3.1 pA; n = 5; paired t-test: P = 0.12). (**L)** Summary of the relative (%) time-courses of potentiation of sI~AHP~ measured in all cells (n = 5 for each condition) under control conditions (0.2% DMSO), in 10 μM ryanodine and in 50 μM CPA. Reduction of the sI~AHP~ amplitude potentiation in the presence of ryanodine (two-way ANOVA with post-hoc Bonferroni test: P \< 0.0001) and of CPA (two-way ANOVA with post-hoc Bonferroni test: P \< 0.0001). (**M)** Ratio of the sI~AHP~ amplitude measured at 0 and 15 min under control conditions (mean ± SEM: 3.9 ± 0.7; n = 5), in ryanodine (2.2 ± 0.3; n = 5; P = 0.04) and in CPA (1.9 ± 0.4; n = 5; P = 0.03).](pone.0230465.g003){#pone.0230465.g003}

Next we tested whether the run-up phase of sI~AHP~ depends on CICR from ryanodine-sensitive stores. Therefore 10 μM ryanodine was applied from the very beginning of the recording. Also under these conditions the sI~AHP~ amplitude increased significantly within the first 15 min of the recording from 27.4 ± 2.6 pA to 58.2 ± 9.3 pA ([Fig 3D--3F, 3J and 3L](#pone.0230465.g003){ref-type="fig"}, n = 5, paired t-test: P = 0.02). Although the sI~AHP~ amplitude increased within 15 min under control conditions as well as in the presence of ryanodine, the extent of the sI~AHP~ amplitude potentiation was significantly reduced in the presence of ryanodine ([Fig 3L](#pone.0230465.g003){ref-type="fig"}; n = 5; two-way ANOVA with post-hoc Bonferroni test: P \< 0.0001). The ratio of the sI~AHP~ amplitude measured at 0 and 15 min under control conditions and in the presence of ryanodine shows that the sI~AHP~ potentiation has been reduced by roughly 50% by ryanodine ([Fig 3M](#pone.0230465.g003){ref-type="fig"}). The extensive attenuation in the sI~AHP~ run-up observed in the presence of ryanodine suggests that Ca^2+^ released by RyR-mediated CICR contributes substantially in mediating the activity-dependent potentiation of sI~AHP~.

Inhibition of Ca^2+^ store refilling reduces the activity-dependent potentiation of sI~AHP~ in rat CA1 pyramidal neurons {#sec013}
------------------------------------------------------------------------------------------------------------------------

The sI~AHP~ activity-dependent potentiation depends on RyR-mediated CICR, as suggested by its reduction by ryanodine. If this is the case, the run-up should be affected when the Ca^2+^-reuptake into the endoplasmic reticulum compartment is inhibited. Cyclopiazonic acid (CPA) is an endoplasmic reticulum Ca^2+^-ATPase blocker that prevents the refilling of depleted Ca^2+^ stores in CA1 pyramidal neurons \[[@pone.0230465.ref027]\]. Consequently, in the presence of CPA no further Ca^2+^ can be released from intracellular stores after an initial release.

CPA was used in the next set of experiments to see whether the suppression of the Ca^2+^ store refilling resulted in a concomitant reduction of the activity-dependent potentiation. CPA (50 μM) was added together with TTX (0.5 μM) and TEA (1 mM) to the bath solution at least 3 minutes before recording the first sI~AHP~ trace. Although the current increased slightly (from 27.5 ± 6.6 pA at 0 min to 39.2 ± 3.1 pA at 15 min; n = 5; [Fig 3G--3I, 3J and 3K](#pone.0230465.g003){ref-type="fig"}), no significant increase in the sI~AHP~ amplitude was observed within the first 15 min ([Fig 3K and 3L](#pone.0230465.g003){ref-type="fig"}) of the recording in the presence of CPA (paired t-test: P = 0.12; n = 5) showing that preventing the refilling of the Ca^2+^ stores by CPA reduces the activity-dependent potentiation as efficiently as depleting the stores by 10 μM ryanodine. Overall the extent of the sI~AHP~ amplitude potentiation was significantly reduced in the presence of CPA (two-way ANOVA with post-hoc Bonferroni test: P \< 0.0001; n = 5; [Fig 3L](#pone.0230465.g003){ref-type="fig"}). The conspicuous reduction by around 50% ([Fig 3M](#pone.0230465.g003){ref-type="fig"}) of the sI~AHP~ amplitude ratio in the presence of CPA further illustrates the impact of ryanodine-sensititve store depletion on the sI~AHP~ potentiation.

Taken together, the results obtained with ryanodine and CPA demonstrate that RyR-mediated CICR is an essential mechanism underlying the activity-dependent potentiation of sI~AHP~ in rat CA1 pyramidal neurons.

Features of sI~AHP~ in CA1 pyramidal neurons from mice lacking type 3 ryanodine receptor (RyR3) and wildtype littermates {#sec014}
------------------------------------------------------------------------------------------------------------------------

The results shown so far (Figs [1](#pone.0230465.g001){ref-type="fig"}--[3](#pone.0230465.g003){ref-type="fig"}) imply that RyR-mediated CICR contributes to the maintenance and potentiation of sI~AHP~ in rat CA1 pyramidal neurons. This leads to the question as to which of the three existing receptor subtypes (RyR1, RyR2 and RyR3) is involved in this process, since ryanodine binds to all three. Both RyR2 and RyR3 are expressed in the CA1 layer, with RyR3 being the most abundant subtype in CA1 pyramidal cells, followed by RyR2 \[[@pone.0230465.ref024], [@pone.0230465.ref045]\]. Moreover, RyR3 was proposed to be specifically responsible for triggering sI~AHP~, as intracellular application of anti-RyR3 antibodies strongly reduced the current amplitude in mouse CA1 pyramidal neurons \[[@pone.0230465.ref032]\]. Therefore, we next investigated whether RyR3 plays a role in the generation and maintenance of sI~AHP~ and is responsible for the activity-dependent potentiation of sI~AHP~ by using knock-out mice lacking RyR3 \[RyR −/−, 33\].

Before studying how the absence of the RyR3 receptor affects the generation, maintenance and activity-dependent potentiation of the sI~AHP~, we investigated whether the loss of RyR3 changed the passive membrane and firing properties of mouse CA1 pyramidal neurons. The mean resting membrane potential of CA1 pyramidal neurons was not affected by the lack of RyR3 (RyR3 −/−) = -66.8 ± 0.6 mV; n = 61; (RyR3 +/+) = -67.0 ± 0.6 mV; n = 60) (P = 0.9, Mann-Whitney test). Also the membrane time constant of CA1 pyramidal neurons in wild-type littermates (RyR3 +/+, 7.5 ± 0.3 ms, n = 60) did not change compared to RyR3 −/− mice (7.5 ± 0.3 ms, n = 61; P = 0.7, Mann-Whitney test). However, the input resistance CA1 pyramidal neurons was significantly lower in RyR3 −/− (204.1 ± 7.5 MΩ, n = 61) compared to RyR3 +/+ littermates (251.2 ± 8.6 MΩ, n = 60) (P \< 0.0001). Conversely, the membrane capacitance of CA1 pyramidal neurons from RyR3 −/− mice (41.6 ± 2.9 pF, n = 61) was higher compared to RyR3 +/+ littermates (32.9 ± 2.1 pF, n = 60, P = 0.03, Mann-Whitney test).

When comparing the firing rates of CA1 pyramidal neurons from RyR3 +/+ and RyR3 −/− littermates in response to increasing current injections, CA1 neurons recorded from RyR3 +/+ mice fired more action potentials, at a higher frequency compared to RyR3 −/− CA1 neurons (P = 0.004, two-way ANOVA with Bonferroni's test) ([Fig 4A--4C](#pone.0230465.g004){ref-type="fig"}).

![Lack of type 3 ryanodine receptor (RyR3) affects the firing properties and sI~AHP~ current density in mouse CA1 pyramidal neurons.\
(**A-B)** action potentials were induced by current injections from 40 pA to 160 pA (in 40 pA step-increments) for 1 s in RyR3 +/+ and RyR3 −/− CA1 pyramidal neurons. The membrane resting potential was -68 mV (A) and -69 mV (B). (**C)** Action potential frequency was higher in RyR3 +/+ compared to RyR3 −/− CA1 pyramidal neurons at the same stimulation strength (P = 0.004, two-way ANOVA with Bonferroni's test). At 40 pA action potentials could not be elicited in either RyR3 +/+ or RyR3 −/− CA1 pyramidal neurons. The action potential frequency did not differ significantly (P = 0.5) for current injections at 80 pA for RyR3 +/+ (0.7 ± 0.2 Hz, n = 32) and RyR3 −/− (0.2 ± 0.1 Hz, n = 37). However, at higher current injections action potential frequencies were substantially different (120 pA: RyR3 +/+ = 1.9 ± 0.4 Hz, n = 27 vs RyR3 −/− = 1.1 ± 0.2 Hz, n = 34, P = 0.0003; and 160 pA RyR3 +/+ = 2.8 ± 0.8 Hz, n = 12 vs RyR3 −/− = .1 ± 0.3 Hz, n = 26, P = 0.001). (**D-E**) Representative sI~AHP~ traces obtained from RyR3 +/+ and RyR3 −/− mouse CA1 pyramidal neurons. (**F-I**) Properties of the sI~AHP~ recorded at steady-state in RyR3 +/+ and RyR3 −/− mice \~15 minutes after the onset of the recording. (**F**) No significant difference was observed for current amplitude (RyR3 +/+ = 42.5 ± 8.1 pA, n = 10 vs RyR3 −/− = 30.5 ± 6.1 pA, n = 7; P = 0.2). (**G)** Similarly, there was no significant difference for sI~AHP~ charge transfer (RyR3 +/+ = 172.9 ± 34.6 pC, n = 10 vs RyR3 −/− = 120.6 ± 22.8 pC, n = 7; P = 0.3) and (**H)** the deactivation time constant of sI~AHP~ (RyR3 +/+ = 3.6 ± 0.3 s, n = 10 vs RyR3 −/− = 3.5 ± 0.3 s, n = 7; P = 0.9). (**I)** sI~AHP~ current density was reduced in RyR3 -/- neurons (RyR3 −/− = 0.8 ± 0.1 pA/pF, n = 7 vs RyR3 +/+ = 1.7 ± 0.5 pA/pF, n = 10; P = 0.03, Mann-Whitney test).](pone.0230465.g004){#pone.0230465.g004}

In whole cell voltage-clamp recordings from CA1 pyramidal neurons in RyR3 +/+ and RyR3 −/− littermates, the sI~AHP~ was elicited with the same pulse protocol previously used to stimulate rat CA1 pyramidal neurons (100 ms long depolarizing voltage steps from -50 mV to +10 mV, repeated every 30 s). The sI~AHP~ was present in both RyR3 +/+ and RyR3 −/− ([Fig 4D and 4E](#pone.0230465.g004){ref-type="fig"}) CA1 pyramidal neuron at the end of the run-up phase, 15 min from the onset of the recording. At this time point the sI~AHP~ amplitude ([Fig 4F](#pone.0230465.g004){ref-type="fig"}; P = 0.2), charge transfer ([Fig 4G](#pone.0230465.g004){ref-type="fig"}; P = 0.3), and deactivation time constant ([Fig 4H](#pone.0230465.g004){ref-type="fig"}; P = 0.9) were similar in CA1 pyramidal neurons from RyR3 +/+ and RyR3 −/− mice. The sI~AHP~ density ([Fig 4I](#pone.0230465.g004){ref-type="fig"}), calculated by normalising the sI~AHP~ amplitude to the membrane capacitance, was reduced in CA1 pyramidal neurons of RyR3 −/− compared to neurons in RyR3 +/+ mice (P = 0.03, Mann-Whitney test), as expected due to the increased membrane capacitance of RyR3 −/− neurons.

These results show that the absence of RyR3 did not prevent the generation and maintenance of the sI~AHP~ in CA1 pyramidal neurons, and fundamental sI~AHP~ properties were not different in RyR3 −/− and RyR3 +/+ ([Fig 4D--4H](#pone.0230465.g004){ref-type="fig"}), with the exception of sI~AHP~ density, which was lower in RyR3 −/− than in RyR3 +/+ CA1 pyramidal neurons ([Fig 4I](#pone.0230465.g004){ref-type="fig"}).

Ryanodine reduces the sI~AHP~ amplitude at steady-state in RyR3 +/+ and RyR3 −/− CA1 pyramidal neurons {#sec015}
------------------------------------------------------------------------------------------------------

The next step was to study the effect of CICR inhibition by ryanodine on the sI~AHP~ measured at steady-state in wild type mice and mice lacking RyR3. At the end of the run-up phase, once the sI~AHP~ was fully potentiated, normally \~15 minutes after the beginning of the recording ([Fig 5G](#pone.0230465.g005){ref-type="fig"}), application of ryanodine (10 μM) to RyR3 +/+ CA1 pyramidal cells reduced the amplitude of the sI~AHP~ by 39.0 ± 6.9% (n = 7, [Fig 5A--5C, 5G and 5I](#pone.0230465.g005){ref-type="fig"}). The sI~AHP~ reduced in amplitude over a period of 15--20 minutes ([Fig 5G](#pone.0230465.g005){ref-type="fig"}), comparable with our observation in rat CA1 pyramidal neurons ([Fig 2D](#pone.0230465.g002){ref-type="fig"}). Thus, ryanodine application has similar effects on the sI~AHP~ measured at steady state in mouse and rat CA1 pyramidal neurons.

![Inhibition of CICR by ryanodine reduced the sI~AHP~ amplitude at steady state in RyR3 +/+ and RyR3 −/− mouse CA1 pyramidal neurons.\
Representative sI~AHP~ traces obtained from RyR3 +/+ (**A**) and RyR3 −/− (**D**) mouse CA1 pyramidal neurons at steady-state, at the end of the run-up phase. Current traces from the same neurons 15 minutes after the application of 10 μM ryanodine (RyR3 +/+ (**B**) and RyR3 −/− (**E**)). (**C** and **F)** Superimposed traces showing the reduction of the sI~AHP~ amplitude. Scale bars in (**F**) apply to all panels, (**A-F**). (**G**) Time course of sI~AHP~ amplitude in the same RyR3 +/+ neuron as shown in A-C. (**H**) Time course of the sI~AHP~ amplitude in the same RyR3 −/− neuron as shown in D-F. (**I)** Overall decrease in the sI~AHP~ amplitude summarized in a box-and-whiskers plot, showing comparable reduction by ryanodine in RyR3 +/+ (mean ± SEM: 39.0 ± 6.9%; median = 36.2%, n = 7) and RyR3 −/− neurons (mean ± SEM: 36.9 ± 9.4%; median = 33.4%, n = 5) (P = 0.9).](pone.0230465.g005){#pone.0230465.g005}

The same experimental conditions were used to study the effect of ryanodine application on RyR3 −/− CA1 pyramidal cells. After the sI~AHP~ was fully potentiated and reached a steady state amplitude ([Fig 5D and 5H](#pone.0230465.g005){ref-type="fig"}), 10 μM ryanodine was applied. Ryanodine application reduced the amplitude of the sI~AHP~ by 36.9 ± 9.4% (n = 7, [Fig 5E, 5F, 5H and 5I](#pone.0230465.g005){ref-type="fig"}). The reduction in sI~AHP~ amplitude caused by ryanodine was comparable in RyR3 +/+ and RyR3 −/− CA1 pyramidal neurons (P = 0.9) ([Fig 5I](#pone.0230465.g005){ref-type="fig"}). These results show that inhibition of CICR by ryanodine has a similar impact on sI~AHP~ measured at steady state in the presence and in the absence of type 3 ryanodine receptors.

Lack of RyR3 affects the activity-dependent potentiation of sI~AHP~ in mouse CA1 pyramidal neurons {#sec016}
--------------------------------------------------------------------------------------------------

In rat CA1 neurons, sI~AHP~ undergoes an activity-dependent potentiation that is sensitive to RyR-mediated CICR \[[Fig 3](#pone.0230465.g003){ref-type="fig"}, 14\]. We therefore investigated whether RyR3 played a specific role in mediating the sI~AHP~ potentiation by measuring and comparing it in RyR3 +/+ and RyR3 −/− CA1 pyramidal neurons. As in the recordings before, when characterizing the run-up phase in rat CA1 pyramidal neurons, the inhibitors for sodium and potassium channels were added to the bath solution at least 3 minutes before recording the first sI~AHP~ trace. The sI~AHP~ started as a small current and increased to a larger amplitude by 15 minutes in RyR3 +/+ (one-way ANOVA, P \< 0.05) and RyR3 −/− (one-way ANOVA, P \< 0.0001) CA1 pyramidal cells ([Fig 6A, 6B and 6D](#pone.0230465.g006){ref-type="fig"}). The starting sI~AHP~ amplitudes in RyR3 +/+ and RyR3 −/− CA1 neurons were not significantly different (P = 0.07, Mann-Whitney test) ([Fig 6C](#pone.0230465.g006){ref-type="fig"}), despite a tendency towards larger initial currents in RyR3 −/− neurons. At the end of the run-up phase, at 15 minutes, the steady-state sI~AHP~ amplitude was also similar in CA1 neurons from RyR3 +/+ and RyR3 −/− mice (P = 0.2) ([Fig 6C](#pone.0230465.g006){ref-type="fig"}).

![CA1 pyramidal neurons lacking type 3 ryanodine receptor (RyR3 −/−) have a faster and reduced activity-dependent potentiation of sI~AHP~.\
(**A, B)** Superimposed traces of the sI~AHP~ recorded at 0 and 15 minutes from RyR3 +/+ and RyR3 −/− CA1 pyramidal neurons. (**C)** Box-and-whiskers plot summarizing the sI~AHP~ amplitudes recorded before the run-up phase (0 min) and at the end of potentiation (15 min). At 0 min the sI~AHP~ peak amplitude in RyR3 +/+ (mean ± SEM: 4.2 ± 1.8 pA; median = 2.3 pA; n = 10) and in RyR3 −/− CA1 pyramidal neurons (mean ± SEM: 9.2 ± 3.4 pA; median = 4.7 pA; n = 7) was similar (P = 0.07, Mann-Whitney test). At steady state (15 min) the amplitude of sI~AHP~ was similar in RyR3 +/+ neurons (mean ± SEM: 45.2 ± 8.1 pA; median = 37.7 pA; n = 10) and in RyR3 −/− (mean ± SEM: 30.5 ± 6.1 pA; median = 27.1 pA; n = 7) (P = 0.2). This shows that a clear potentiation was observed for both RyR3 +/+ (P = 0.0006, paired t-test) and RyR3 −/− (P = 0.006, paired t-test) neurons, because the sI~AHP~ amplitude at steady state was clearly larger when compared with sI~AHP~ amplitude at the beginning of the recording. (**D)** Time course of relative amplitude increase of sI~AHP~ during the first 15 min of the recording, with current amplitudes normalised to the starting current measured at 0 min. The sI~AHP~ potentiation was overall larger in RyR3 +/+ than in RyR3 −/− CA1 pyramidal cells (two-way ANOVA with Bonferroni's test, P \< 0.001). (**E)** The time constant (τ) of sI~AHP~ potentiation was obtained by fitting a mono-exponential function to the sI~AHP~ amplitude during the run-up phase of each individual experiment. The time constant of potentiation was faster in RyR3 −/− (mean ± SEM: 3.1 ± 0.7 min; median = 3.2 min; n = 7) compared to RyR3 +/+ CA1 neurons (mean ± SEM: 6.7 ± 1.1 min; median = 5.6 min; n = 10) (P = 0.043).](pone.0230465.g006){#pone.0230465.g006}

However, the sI~AHP~ amplitude at steady state was consistently and significantly larger than the sI~AHP~ amplitude at the beginning of recording in both RyR3 +/+ (P = 0.0006, n = 10, paired t-test) and in RyR3 −/− CA1 pyramidal neurons (P = 0.006, n = 7, paired t-test) ([Fig 6C](#pone.0230465.g006){ref-type="fig"}), revealing that some activity-dependent potentiation of the current occurred both in the presence and in the absence of RyR3. Interestingly, the relative sI~AHP~ potentiation was more pronounced in RyR3 +/+ CA1 pyramidal neurons (two-way ANOVA, P \< 0.001) ([Fig 6D](#pone.0230465.g006){ref-type="fig"}). This was further corroborated by comparing the ratio of the sI~AHP~ amplitude measured at 0 and 15 minutes, which was lower in RyR3 −/− (5.0 ± 1.0, n = 7) than in RyR3 +/+ (43.5 ± 19.1, n = 10) neurons (P = 0.02, Mann-Whitney test) ([Fig 7G](#pone.0230465.g007){ref-type="fig"}). Additionally, the time constant of the sI~AHP~ potentiation was lower in RyR3 −/− than in RyR3 +/+ CA1 neurons (P = 0.043) ([Fig 6E](#pone.0230465.g006){ref-type="fig"}). These results suggest that lack of RyR3 leads to a faster and reduced activity-dependent potentiation of sI~AHP~.

![Type 3 ryanodine receptor (RyR3) is a main player in the CICR that mediates the activity-dependent potentiation of sI~AHP~ in mouse CA1 pyramidal neurons.\
(**A**, **B)** Superimposed traces of the sI~AHP~ recorded at 0 and 15 minutes from RyR3 +/+ (**A**) and RyR3 −/− (**B**) CA1 pyramidal neurons in the presence of 10 μM ryanodine from the outset of the recordings. (**C)** Summary box-and-whiskers plot of the sI~AHP~ amplitudes recorded at 0 min and at 15 min in the presence of ryanodine (10 μM). At 0 min the sI~AHP~ amplitudes in RyR3 +/+ CA1 neurons (mean ± SEM: 12.1 ± 3.7 pA; median = 10.4 pA; n = 5) and in RyR3 −/− CA1 pyramidal neurons (mean ± SEM: 39.9 ± 12.4 pA; median = 21.2 pA; n = 7) were not significantly different (P = 0.06, Mann-Whitney test). At 15 min the current in RyR3 +/+ (mean ± SEM: 45.6 ± 12.1 pA; median = 36.0 pA; n = 5) and in RyR3 −/− (mean ± SEM: 61.0 ± 16.3 pA; median = 41.6 pA; n = 7) was similar (P = 0.4, Mann-Whitney test). In the presence of ryanodine (10 μM) from the onset, RyR3 +/+ cells had a larger sI~AHP~ at 15 minutes than at 0 minute (P = 0.047, n = 5, t-test with Welch correction), while RyR3 −/− neurons had similar sI~AHP~ amplitudes at 0 and 15 minutes (P = 0.3, n = 7, Mann-Whitney test). (**D)** Time course of relative increase of sI~AHP~ during the first 15 min of the recording in the presence of ryanodine (10 μM), with current amplitudes normalized to the starting current measured at 0 min. The sI~AHP~ potentiation was overall similar in RyR3 +/+ and RyR3 −/− CA1 cells (P = 0.17, two-way repeated measures ANOVA). (**E)** The time constant (τ) of sI~AHP~ potentiation in RyR3 +/+ CA1 neurons (mean ± SEM: 3.4 ± 0.9 min; median = 2.6 min; n = 5) and in RyR3 −/− (mean ± SEM: 2.0 ± 0.6 min; median = 1.3 min; n = 7) was similar (P = 0.2). (**F)** Summary bar chart comparing the sI~AHP~ amplitude from RyR3 +/+ and RyR3 −/− mice in the presence and absence of ryanodine. Ryanodine increased the initial amplitude of sI~AHP~ in RyR3 +/+ (P = 0.02, Mann-Whitney test) and RyR3 -/- CA1 neurons (P = 0.045, t-test with Welch correction), but it did not affect the current measured at 15 minutes in either RyR3 +/+ (P \> 0.9) or RyR3 −/− CA1 neurons (P = 0.1, Mann-Whitney test). (**G)** Summary bar chart comparing ratios of the sI~AHP~ amplitude measured at 0 and 15 min from RyR3 +/+ and RyR3 −/− mice with or without ryanodine. Ryanodine did not significantly decrease the sI~AHP~ ratio in RyR3 −/− CA1 neurons, and did not affect the ratio in RyR3 +/+ CA1 neurons, in spite of an apparent trend (one-way ANOVA-Kruskal-Wallis test with Dunn's multiple comparison test, P \> 0.05 for both comparisons). In the presence of ryanodine from the onset, the sI~AHP~ ratio was not significantly different between RyR3 +/+ CA1 cells (5.5 ± 1.8, n = 5) and RyR3 −/− CA1 neurons (3.2 ± 1.8, n = 7) (one-way ANOVA-Kruskal-Wallis test with Dunn's multiple comparison test, P \> 0.05 for this comparison).](pone.0230465.g007){#pone.0230465.g007}

CICR underlying the activity-dependent potentiation of sI~AHP~ is mostly dependent on RyR3 in mouse CA1 pyramidal neurons {#sec017}
-------------------------------------------------------------------------------------------------------------------------

Our results obtained from rat CA1 pyramidal neurons showed that inhibition of CICR by ryanodine and CPA application substantially reduced the activity-dependent potentiation of sI~AHP~ ([Fig 3](#pone.0230465.g003){ref-type="fig"}). If RyR3 is the molecular determinant for the activity-dependent potentiation of the sI~AHP~, then potentiation in RyR3 −/− mice should not be affected by ryanodine.

In the presence of ryanodine (10 μM) from the start of the recording, in RyR3 +/+ CA1 neurons the sI~AHP~ amplitude significantly increased from an initial value of 12.1 ± 3.7 pA to 45.6 ± 12.1 pA, when the sI~AHP~ was fully potentiated (n = 5, P = 0.047, t-test with Welch correction) ([Fig 7A, 7C and 7F](#pone.0230465.g007){ref-type="fig"}). However, the sI~AHP~ amplitude in RyR3 −/− CA1 neurons recorded at the beginning (39.9 ± 12.4 pA) was not significantly different from the amplitude recorded at the end of the run-up phase (61.0 ± 16.3 pA; n = 7, P = 0.3, Mann-Whitney test) ([Fig 7B, 7C and 7F](#pone.0230465.g007){ref-type="fig"}). Indeed, the relative change of sI~AHP~ amplitude throughout the run-up phase was comparable between RyR3 +/+ and RyR3 −/− CA1 neurons (P = 0.17, two-way repeated measures ANOVA) ([Fig 7D](#pone.0230465.g007){ref-type="fig"}). Also, the time for the sI~AHP~ to reach full potentiation was not different between RyR3 +/+ and RyR3 −/− CA1 cells (P = 0.2) ([Fig 7E](#pone.0230465.g007){ref-type="fig"}). The similarity in run-up in the presence of ryanodine is also seen when comparing the ratio of the sI~AHP~ amplitude recorded at 0 minutes and 15 minute, which was not significantly different between RyR3 +/+ and RyR3 −/− CA1 neurons (one-way ANOVA-Kruskal-Wallis test with Dunn's multiple comparison test, P \> 0.05) ([Fig 7G](#pone.0230465.g007){ref-type="fig"}). The similarity of the relative extent of run-up ([Fig 7D and 7E](#pone.0230465.g007){ref-type="fig"}) and of the amplitude ratio ([Fig 7G](#pone.0230465.g007){ref-type="fig"}) indicates that no difference in sI~AHP~ potentiation between knock-out and wild-type animals was observed when ryanodine was applied from the beginning of the recordings.

When comparing the sI~AHP~ amplitudes recorded without ryanodine (Figs [6A--6C](#pone.0230465.g006){ref-type="fig"} and [7F](#pone.0230465.g007){ref-type="fig"}) with those where ryanodine was present from the beginning of the recording ([Fig 7A--7C and 7F](#pone.0230465.g007){ref-type="fig"}) in RyR3 +/+ and RyR3 −/− CA1 neurons, it becomes evident that the absence of RyR3 leads to a reduction in the activity-dependent potentiation of sI~AHP~ by increasing its initial amplitude. The initial sI~AHP~ amplitude (0 min) was significantly increased in the presence of ryanodine in RyR3 +/+ CA1 neurons (P = 0.02, Mann-Whitney test) and, to an even larger extent, in RyR3 −/− (P = 0.045, t-test with Welch correction) ([Fig 7F](#pone.0230465.g007){ref-type="fig"}). Conversely, the sI~AHP~ amplitude measured at the end of the run-up phase (15 min) was not different between RyR3 +/+ and RyR3 −/− CA1 cells (P = 0.4, Mann-Whitney test; [Fig 7A--7C and 7F](#pone.0230465.g007){ref-type="fig"}), and was similar with and without ryanodine applied from the beginning of the recording in RyR3 +/+ CA1 neurons (P \> 0.9) and in RyR3 −/− CA1 neurons (P = 0.1, Mann-Whitney test) ([Fig 7F](#pone.0230465.g007){ref-type="fig"}). The increase in initial current amplitude, caused by ryanodine and particularly prominent in the absence of RyR3, combined with no change in the current amplitude at the end of the run-up phase results in the reduction in potentiation observed when reducing CICR by ryanodine, and especially pronounced in RyR3 −/− CA1 neurons. Thus, overall inhibition of CICR by ryanodine had an effect on the starting but not final sI~AHP~ amplitudes both in the presence and absence of RyR3. Taken altogether, the data show that inhibition of CICR by ryanodine removed the differences in the extent and rate of potentiation of sI~AHP~ between RyR3 +/+ and RyR3 −/− CA1 neurons, suggesting that type 3 ryanodine receptors play a specific role in mediating the activity-dependent potentiation of this current.

Discussion {#sec018}
==========

This study shows that ryanodine receptor-mediated calcium-induced calcium release contributes both to the amplitude of the sI~AHP~ at steady state and its activity-dependent potentiation in rat and mouse hippocampal pyramidal neurons. In particular, analysis of CA1 pyramidal neurons lacking type 3 ryanodine receptors (RyR3) has revealed that RyR3 plays an essential and specific role in shaping the activity-dependent potentiation of the sI~AHP~.

RyR-mediated CICR contributes to the generation of currents underlying long-lasting afterhyperpolarisations in a variety of neurons, including guinea pig dorsal vagal nucleus neurons \[[@pone.0230465.ref020]\], sympathetic neurons \[[@pone.0230465.ref046]\], superior cervical ganglion neurons \[[@pone.0230465.ref047]\], nodose ganglion neurons \[[@pone.0230465.ref048]\], afterhyperpolarising (AH) myenteric plexus neurons in guinea pig ileum \[[@pone.0230465.ref049]\] and duodenum \[[@pone.0230465.ref050]\], rabbit otic ganglion neurons \[[@pone.0230465.ref051]\], and layer II-III sensorimotor neocortical completely adapting neurons \[[@pone.0230465.ref019]\]. In these studies ryanodine, applied at concentrations of 5--20 μM led to reductions in the amplitude of the sAHP and the corresponding sI~AHP~ ranging from \~50% \[[@pone.0230465.ref019], [@pone.0230465.ref046], [@pone.0230465.ref049]\] to complete inhibition \[[@pone.0230465.ref020], [@pone.0230465.ref048], [@pone.0230465.ref050]\].

The contribution of RyR-mediated CICR to the generation of the sAHP or the sI~AHP~ in hippocampal neurons is more controversial. In CA3 pyramidal neurons from organotypic slice cultures sI~AHP~ was inhibited by \~50% upon application of ryanodine \[[@pone.0230465.ref010]\], which is comparable to the \~30% reduction observed in CA1-CA3 cultured hippocampal neurons \[[@pone.0230465.ref052]\], suggesting that CICR plays a role in the activation of sI~AHP~. In CA1 pyramidal neurons, our study reports a reduction of the sI~AHP~ of 23.3 ± 3.7% ([Fig 2E](#pone.0230465.g002){ref-type="fig"}) from rat and 39.0 ± 6.9% ([Fig 5I](#pone.0230465.g005){ref-type="fig"}) from mouse hippocampal slices in response to the application of ryanodine once the current had reached its steady-state amplitude. Therefore our results are in good agreement with those in CA3 and cultured hippocampal neurons \[[@pone.0230465.ref010], [@pone.0230465.ref052]\], and with other studies on CA1 pyramidal neurons in slices \[[@pone.0230465.ref014], [@pone.0230465.ref021], [@pone.0230465.ref029], [@pone.0230465.ref030], [@pone.0230465.ref053]\], but differ from those of Zhang et al. \[[@pone.0230465.ref017]\] and Torres et al. \[[@pone.0230465.ref031]\], who failed to observe any effect of ryanodine on sI~AHP~ and sAHP in CA1 neurons, although Torres et al. \[[@pone.0230465.ref031]\] reported a reduction in sAHP in response to other CICR inhibitors (dantrolene and ruthenium red).

The concentration of ryanodine used in our study was selected to inhibit CICR in CA1 pyramidal neurons. While our study does not address the mechanism of CICR inhibition by 10 μM ryanodine, this concentration is in a range that has been reported to change theconductance properties of RyR receptors by keeping them in a subconducting state with high open probability, thereby depleting the ryanodine sensitive Ca^2+^ stores and preventing further Ca^2+^ release \[[@pone.0230465.ref054], [@pone.0230465.ref055]\]. In physiological settings, this has been shown to reduce both the amplitude and duration of evoked Ca^2+^ transients and sAHP in myenteric neurons \[[@pone.0230465.ref049]\], to decrease the amplitude of action potential-evoked Ca^2+^ transients \[[@pone.0230465.ref028]\] and inhibit caffeine-induced Ca^2+^ signals \[[@pone.0230465.ref026], [@pone.0230465.ref027]\] in CA1 pyramidal neurons. The time course of the effect of ryanodine on the fully developed sI~AHP~ showed that a clear sI~AHP~ inhibition was achieved in 10--20 min in our experiments, similar to what was observed in other studies on CA1 pyramidal neurons in acute slices \[[@pone.0230465.ref029], [@pone.0230465.ref030], [@pone.0230465.ref053]\], cultured hippocampal neurons \[[@pone.0230465.ref052]\] and vagal motorneurons \[[@pone.0230465.ref020]\].

The contribution of CICR to the generation of sI~AHP~ in CA1 neurons is further supported by our finding that caffeine, which activates ryanodine receptors causing calcium release \[[@pone.0230465.ref037], [@pone.0230465.ref056]\], enhances the sI~AHP~ amplitude. This finding is in line with similar observations in CA3 \[[@pone.0230465.ref057]\] and CA1 pyramidal neurons \[[@pone.0230465.ref031]\], but differs from the lack of effect of caffeine reported by Zhang et al. \[[@pone.0230465.ref017]\]. In AH myenteric neurons, application of caffeine (5 mM) was usually accompanied by a transient increase in sI~AHP~, followed by a decrease of the current \[[@pone.0230465.ref050]\]. This is similar to what we observed in CA1 pyramidal neurons upon application of caffeine at a lower concentration (0.5 mM; [Fig 1A--1E](#pone.0230465.g001){ref-type="fig"}). Furthermore, our finding suggests that the observed decrease in sI~AHP~ amplitude results from the inhibition of phosphodiesterases by caffeine \[[@pone.0230465.ref041]\]. This leads to a slow but significant increase in cAMP and activation of protein kinase A (PKA), which is known to suppress the sI~AHP~ \[[@pone.0230465.ref043]\]. This is further supported by our evidence that inhibition of PKA by Rp-cAMPS prevents the caffeine-mediated reduction of sI~AHP~ ([Fig 1F--1J](#pone.0230465.g001){ref-type="fig"}). Consequently, caffeine exerts a purely enhancing effect on the current under PKA inhibition, as expected upon increase in intracellular Ca^2+^ levels. Our observations further suggest that PKA activation, as a consequence of phosphodiesterase inhibition, might underlie the inhibitory effect of caffeine on the sI~AHP~ in different types of neurons, as reported in other studies \[[@pone.0230465.ref020], [@pone.0230465.ref050]\].

Low concentrations of caffeine increase action potential-induced Ca^2+^ transients in CA1 pyramidal neurons, and this effect is dependent on facilitation of CICR and independent from activation of the cAMP-PKA pathway \[[@pone.0230465.ref028]\], similar to what we have shown for the sI~AHP~ modulation by caffeine. Taken together, these findings suggest that caffeine might enhance sAHP and spike frequency adaptation by facilitating CICR and increasing action potential-induced Ca^2+^ transients under physiological conditions in CA1 neurons.

Taken altogether, the effects of pharmacological modulators of CICR in our study suggest that ryanodine receptor-mediated CICR contributes to the generation of sI~AHP~ and to its amplitude at steady state. To further address the role of specific RyR subtypes in the generation of sI~AHP~, we have analysed the current in CA1 pyramidal neurons from mice lacking type 3 ryanodine receptors (RyR3 −/−). Although the lack of RyR3 does not lead to significant abnormalities in overall health, appearance, and basic sensorimotor functions, RyR3 deficient mice present specific behavioural abnormalities that reflect their role in brain regions where they are highly expressed, such as the hippocampus and the striatum. Thus, several studies performed on RyR3 −/− mice have reported irregular responses in locomotor activity and social behaviour \[[@pone.0230465.ref058]\], contextual learning \[[@pone.0230465.ref059]\] and spatial learning \[[@pone.0230465.ref060]\]. Indeed, LTP in the hippocampal CA1 region \[[@pone.0230465.ref060], [@pone.0230465.ref061]\] and dopamine release in the striatum \[[@pone.0230465.ref062]\] are impaired in Ryr3 -/- mice. In our specific case, the salient features of sI~AHP~ (amplitude, charge transfer, time course of decay) were similar in the presence or absence of RyR3, despite a reduction in current density that was linked to a concomitant increase in membrane capacity in RyR3 deficient mice. Our finding suggests that the absence of RyR3 does not significantly impair the generation of sI~AHP~ and RyR3 does not significantly contribute to the absolute size of this current at the steady state. This finding contrasts with a report that intracellular application of anti-RyR3 antibodies caused a 70% reduction in sI~AHP~ and occluded the effect of ryanodine on this current in mouse CA1 pyramidal neurons \[[@pone.0230465.ref032]\]. In our experiments, ryanodine reduced the sI~AHP~ amplitude similarly in neurons from RyR3 +/+ (39.0 ± 6.9%) and RyR3 −/− (36.9 ± 9.4%) mice ([Fig 5](#pone.0230465.g005){ref-type="fig"}). Possible reasons for this discrepancy might be due to the different experimental conditions, such as the voltage protocols used to elicit sI~AHP~; in particular, the 1 s-long depolarising voltage steps used by Van de Vrede et al. \[[@pone.0230465.ref032]\] have been shown to cause "overcharging" of ryanodine-sensitive stores in mouse CA1 pyramidal neurons \[[@pone.0230465.ref026]\], which might have led to an over-estimation of the contribution of RyR-mediated calcium release to the sI~AHP~ under those experimental conditions when compared to more physiological depolarising stimuli to elicit this current. The other experimental difference is the use of a specific knock-out missing the RyR3 receptor instead of the intracellular application of antibody \[[@pone.0230465.ref032]\]. In the absence of an independent validation of the specific blocking effect of the anti-RyR3 antibody on RyR3 channel activity \[[@pone.0230465.ref063]\], it cannot be excluded that the pronounced effect of the antibody on sI~AHP~ \[[@pone.0230465.ref032]\] might be due partly to off-target effects. In the case of the RyR3 knock-out mice, it is worth noticing that, even when multiple subtypes of ryanodine receptors are expressed in the same cell type \[RyR1, RyR2 and RyR3 in the case of CA1 pyramidal neurons, 23, 24, 25\], available experimental evidence supports the formation of homomeric channels \[[@pone.0230465.ref064]\], and knockout of the RyR3 gene does not affect the expression level or the developmental regulation of the RyR1 and RyR2 isoforms in the brain \[[@pone.0230465.ref045], [@pone.0230465.ref060]\]. Thus, the lack of significant changes in the steady state size of the sI~AHP~ and its modulation by ryanodine in RyR3 −/− compared to RyR3 (+/+) (Figs [4](#pone.0230465.g004){ref-type="fig"} and [5](#pone.0230465.g005){ref-type="fig"}) is unlikely to be due to a compensatory up-regulation of RyR1 or RyR2 expression in CA1 neurons. Given that RyR3 −/− mice present behavioural abnormalities (see above), we cannot exclude that adaptive changes may alter expression profiles of other genes in the brain. However, it is worth noticing that no previous studies dealing with RyR3 −/− mice have shown altered profiles in exhaustive protein and gene expression. In the hippocampus, for example, it has been reported that expression levels and distribution of the AMPA receptor subunits GluR1-4, the NMDA receptor subunit NR1 and PSD-95 are not altered in RyR3 −/− mice \[[@pone.0230465.ref061]\]. Also the expression levels of the three IP~3~ receptors and the distribution patterns of the Ca^2+^-binding proteins parvalbumin, calbindin and calretinin immunoreactivity in mutant mice resemble those of wild-type controls \[[@pone.0230465.ref060]\]. Finally, RyR3 mutant mice do not display obvious alterations in the number, distribution or gross and fine morphology (i.e. spine density) of hippocampal principal neurons, interneurons or glial cells as compared to their wild-type counterparts \[[@pone.0230465.ref045], [@pone.0230465.ref060]\].

Repeated activation of CA1 pyramidal neurons with depolarising current pulses \[[@pone.0230465.ref015]\] or action potential firing at gamma-related (50 Hz) frequencies \[[@pone.0230465.ref016]\] causes a long-lasting, gradual decrease in membrane excitability associated with an increase in spike frequency adaptation and a potentiation of the sAHP. Additionally, voltage-clamp analysis has revealed a concomitant activity-dependent potentiation of sI~AHP~ in rat CA1 pyramidal neurons, critically dependent on the activation of L-type voltage-gated Ca^2+^ channels and ryanodine-sensitive CICR \[[@pone.0230465.ref014]\]. Our results support the findings of Borde et al. \[[@pone.0230465.ref014]\] and extend them to mouse CA1 pyramidal neurons. Most importantly, a detailed analysis of the sI~AHP~ potentiation in CA1 neurons lacking RyR3 receptors has revealed that, in the absence of RyR3, the activity-dependent potentiation of sI~AHP~ is reduced and its time course is faster than in CA1 neurons expressing RyR3 ([Fig 6](#pone.0230465.g006){ref-type="fig"}). The differences in the extent and rate of potentiation of sI~AHP~ between RyR3 +/+ and RyR3 −/− CA1 neurons are removed by overall inhibition of CICR by ryanodine ([Fig 7](#pone.0230465.g007){ref-type="fig"}). Our findings suggest that type 3 ryanodine receptors are not essential for the generation and maintenance of sI~AHP~, but play a specific and distinctive role in shaping the extent and time course of the activity-dependent potentiation of this current. Our data, however, do not provide any direct indication as to how ryanodine-sensitive CICR, and in particular RyR3, contribute to the activity-dependent potentiation of the sI~AHP~. A potential mechanism might be linked to a distinctive property of RyR3 compared to other ryanodine receptors, namely their low sensitivity to inactivation at high calcium concentration \[[@pone.0230465.ref026], [@pone.0230465.ref065]\]. The resulting sustained RyR3 activity at elevated Ca^2+^ concentrations would make the RyR3 channels particularly suitable to provide a more sustained calcium release efflux from the endoplasmic reticulum when stimulated by increasing concentration of Ca^2+^ released by other calcium release channels, or by calcium channels on the plasma membrane \[[@pone.0230465.ref060]\]. This could also explain the shorter time course of sI~AHP~ potentiation observed in CA1 neurons in the absence of RyR3 ([Fig 6D and 6E](#pone.0230465.g006){ref-type="fig"}).

A second mechanism might result from the interaction between VGCCs in the plasma membrane and RyR-dependent calcium release. In CA1 pyramidal neurons L-type VGCCs are functionally coupled to RyR3, providing the Ca^2+^ influx necessary for RyR3-mediated CICR \[[@pone.0230465.ref066]\], and to the activation of sI~AHP~ \[[@pone.0230465.ref007], [@pone.0230465.ref009]\]. Ca^2+^-dependent inactivation is a negative feedback mechanism whereby Ca^2+^ ions restrict their own entry into the cell by one of the main routes of Ca^2+^ influx, the VGCCs \[[@pone.0230465.ref067]\]. In thalamo-cortical relay neurons RyR-dependent CICR enhances the Ca^2+^-dependent inactivation of L-type VGCCs \[[@pone.0230465.ref068]\]. If a similar interplay is present between L-type Ca^2+^ channels and RyR-mediated CICR in CA1 neurons, this might potentially explain the increase in the amplitude of sI~AHP~ at the start of the recordings observed in the presence of ryanodine, especially in RyR3 deficient neurons ([Fig 7F](#pone.0230465.g007){ref-type="fig"}). A reduction of CICR in the absence of RyR3 receptors would lead to a reduced Ca^2+^-dependent inactivation of the L-type Ca^2+^ current, eliciting in turn a larger initial sI~AHP~.

A third potential mechanism might result from a different mode of activation of RyR channels, namely store-overload-induced Ca^2+^ release (SOICR) \[[@pone.0230465.ref069]\]. The repetitive stimulation leading to Ca^2+^ influx and underlying the activity-dependent potentiation of sI~AHP~ might increase Ca^2+^ uptake by the endoplasmic reticulum, resulting in Ca^2+^ overload and subsequently activation of RyRs by luminal Ca^2+^ and SOICR, in analogy to what has been observed in cardiac cells \[[@pone.0230465.ref070]\]. SOICR has primarily been shown to be mediated by RyR2, with RyR1 having a lower sensitivity, in cardiac and skeletal muscle cells, as well as in HEK293 cells expressing recombinant RyR1 and RyR2 \[[@pone.0230465.ref071]\], but has not been shown in neurons or linked to RyR3 function. However, a store Ca^2+^ sensing gate structure has been identified in RyR2 and is conserved in all types of RyRs \[[@pone.0230465.ref072]\]. In view of this structural similarity, it is tempting to speculate that RyR3 might mediate SOICR in response to repetitive activity in CA1 neurons, and this might specifically contribute to the activity-dependent potentiation of sI~AHP~.

While our study has revealed a specific role for RyR3 in the activity-dependent potentiation of sI~AHP~, this receptor does not seem to play a major role in the generation and maintenance of sI~AHP~, as inferred from the unaltered action of ryanodine on the steady state current in the presence and absence of RyR3. This prompts the question as to the contribution of other RyR isoforms to the generation of sI~AHP~. Since RyR2 and RyR3 are the predominant subtypes expressed in hippocampal neurons \[[@pone.0230465.ref045]\], RyR2 is the most plausible candidate. The role of RyR2 in the sAHP/sI~AHP~ generation is strongly supported by a recent study \[[@pone.0230465.ref021]\], showing that protein complexes formed by Ca~V~1.3 Ca^2+^ channels, RyR2 and K~Ca~3.1 potassium channels and stabilised by junctophilin (JPH 3 and 4) proteins enable VGCC and CICR to act in tandem as Ca^2+^ sources to shape the generation of sI~AHP~. Taken together, our results and the results presented by Sahu et al. \[[@pone.0230465.ref021]\] open the intriguing possibility that different RyR isoforms might be differentially coupled to the generation and maintenance of sI~AHP~ on one hand, and its activity-dependent plasticity on the other, possibly through functional or physical segregation of signalling complexes. This hypothesis could be tested in future studies, possibly by using alternative, selective down-regulation strategies for RyR isoforms, such as antisense oligonucleotides \[[@pone.0230465.ref073]\] or short hairpin RNA \[[@pone.0230465.ref074]\], that have proven successful in cellular and behavioural studies.

The modulation of activity-dependent potentiation of sI~AHP~ by RyR3-mediated CICR shown in this study is likely to contribute to plasticity of intrinsic neuronal excitability and act postsynaptically to control the flow of synaptic signals \[[@pone.0230465.ref013]\], regulate the threshold for induction of long-term potentiation in hippocampal neurons \[[@pone.0230465.ref075]\], and play a critical role in learning and memory \[[@pone.0230465.ref076]--[@pone.0230465.ref079]\].
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